乐铂单药治疗42例原发性支气管肺癌  

Lobaplatin as a single agent in the treatment of 42 cases with lung cancer

作　　者：冯光丽[1] 廖美琳[1] 赵家美[1] 张心敏[1] 陈智伟[1] 白皓[1] 钟华[1] 

机构地区：[1]上海市胸科医院肺科,上海200030

出　　处：《中国癌症杂志》2000年第4期306-308,共3页China Oncology

摘　　要：评价德国ASTA药物公司研制的新化疗药物乐铂对小细胞及非小细胞肺癌的治疗效果和不良反应。方法 :治疗原发性支气管肺癌 42例 ,初治 2 5例 ,复治 17例 ;小细胞肺癌 34例 ,非小细胞肺癌 8例。单用乐铂5 0mg m2 静脉滴注 ,共 2个周期 ,2个周期间隔 2 1天。结果 :总有效率 30 9% ,其中部分缓解 (PR) 13例 ;小肺癌有效率 38 2 % ,非小细胞肺癌均无效。该药的剂量限制性毒性为骨髓抑制 ,白细胞、血色素下降轻微 ,Ⅲ—Ⅳ度血小板下降 (周期数 ,下同 )为 4 6 % (1例因血小板下降死亡 ) ,Ⅰ—Ⅱ度下降为 11 8% ,恶心、呕吐发生率 6 4 3% ,均为Ⅰ—Ⅱ度 ,无Ⅲ—Ⅳ度。结论 :乐铂单药治疗对小细胞肺癌疗效较好 ,毒副反应轻 ,主要毒性为血小板降低 ,肾脏毒性不明显 。Purpose:To evaluate the efficacy and toxicity of using lobaplatin, a new chemotherapy drug of ASTA Company,to treat small cell and non small cell lung cancer. Methods:42 patients of primary bronchogenic carcinoam treated with lobaplatin only,25 cases were primary treatment and 17 were retreated cases. 34 cases were small cell lung cancer, 8 cases were non small cell lung cancer. Lobaplatin was administered at single dose of 50 mg/m 2 by venous instillation,repeated every 21days, given as 2 cycles.Results:Total response rate was 30.9%.partial response in 13 patients. The response rate was 38.2% in small cell lung cancer group, no response in non small cell lung cancer group.The dose limiting toxicity was bone marrow depression, leukopenia while hypochromia was slight;grade Ⅲ and Ⅳ thrombocytopenia was 4.6%(one died of blooding),grade Ⅰ and Ⅱ was 11.8%. Nausea and vomiting was 64.3%, grade Ⅰ to Ⅱ, no grade Ⅲ—Ⅳ. Conclusions:Lobaplatin is effective in treating small cell lung cancer, the side effect are light, the main toxicity being thrombocytopenia, no obvious nephrotoxicity. It can be used in the treatment of small cell lung cancer.

关 键 词：原发性支气管肺癌 乐铂 药物治疗 

分 类 号：R734.205[医药卫生—肿瘤] R730.53[医药卫生—临床医学]